Replies to post #102196 on Biotech Values

[oc631]

That’s possible but not likely, IMO. A more likely reason for the small new PK study is that Roche isn’t sure ITMN-191 is worth the money for a large phase-2b program when there are newer PI’s that are safer, more potent, and don’t require ritonavir boosting.

If Roche looks to another PI considering the contractual liability due Intermune. You know where I stand on that.